Health care law agency Frier Levitt has analyzed FDA enforcement actions towards “exploration only” peptide vendors. Their summary: the FDA considers an item’s classification based on its intended use, not its disclaimers. When Web sites consist of dosage guides, reconstitution instructions, or back